Chronic inhibition of farnesyl pyrophosphate synthase improves endothelial function in spontaneously hypertensive rats

Biochemical Pharmacology

Volumn 80, Issue 11, 2010, Pages 1684-1689

  Chen, Guo Ping ^a   Li, Liang ^a   Yang, Yin ^a   Fu, Michael ^b   Yao, Lei ^a   Wu, Tao ^a   Zhang, Xiao Qin ^c   Hu, Shen Jiang ^a,d  

^a ZHEJIANG UNIVERSITY   (China)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d Immunology Division   (China)

Author keywords

Alendronate; Endothelial nitric oxide synthase; Endothelium function; Farnesyl pyrophosphate synthase; Spontaneously hypertensive rat

Indexed keywords

ALENDRONIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GERANYLTRANSFERASE; MEVALONIC ACID; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; DIMETHYLALLYLTRANSFERASE; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SPONTANEOUSLY HYPERTENSIVE RAT; THORACIC AORTA; TIME; WISTAR KYOTO RAT;

ALENDRONATE; ANIMALS; AORTA, THORACIC; DIMETHYLALLYLTRANSTRANSFERASE; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HYPERTENSION; MALE; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TIME FACTORS; VASODILATION;

EID: 77957900159     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.08.015     Document Type: Article

References (38)

1. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 1999, 31:23-37.
2. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109:III27-III32.
3. Landmesser U., Drexler H. Endothelial function and hypertension. Curr Opin Cardiol 2007, 22:316-320.
4. Boulanger C.M. Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol 1999, 31:39-49.
5. Gokce N. L-arginine and hypertension. J Nutr 2004, 134:2807s-2811s.
6. Massion P.B., Feron O., Dessy C., Balligand J.L. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 2003, 93:388-398.
7. Yetik-Anacak G., Catravas J.D. Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vascul Pharmacol 2006, 45:268-276.
8. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998, 273:24266-24271.
9. Ming X.F., Viswambharan H., Barandier C., Buffieux J., Kaibuchi K., Rusconi S., et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002, 22:8467-8477.
10. Brandes R.P. Statin-mediated inhibition of Rho: only to get more NO?. Circ Res 2005, 96:927-929.
11. Rikitake Y., Liao J.K. Rho GTPases, statins, and nitric oxide. Circ Res 2005, 97:1232-1235.
12. Roskoski R. Protein prenylation: a pivotal posttranslational process. Biochem Biophys Res Commun 2003, 303:1-7.
13. Casey P.J. Protein lipidation in cell signaling. Science 1995, 268:221-225.
14. Chen G.P., Yao L., Lu X., Li L., Hu S.J. Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in spontaneously hypertensive rats. Acta Pharmacol Sin 2008, 29:1181-1186.
15. Li L., Hu S.J., Dong H.T., Kang L., Chen N.Y., Fang Y.Q. Alterations in gene expression of series key enzymes in mevalonic acid pathway detected by RNA array in spontaneously hypertensive rats. Chin J Pathophysiol 2008, 24:54-59.
16. Li L., Chen G.P., Yang Y., Ye Y., Yao L., Hu S.J. Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats. Biochem Pharmacol 2010, 79:399-406.
17. Szkopińska A., Płochocka D. Farnesyl diphosphate synthase; regulation of product specificity. Acta Biochim Pol 2005, 52:45-55.
18. Vanhoutte P.M., Feletou M., Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol 2005, 144:449-458.
19. Chou T.C., Yen M.H., Li C.Y., Ding Y.A. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 1998, 31:643-648.
20. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000, 373:231-241.
21. Roelofs A.J., Thompson K., Gordon S., Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006, 12(20 Suppl):6222s-6230s.
22. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Mönkkönen J., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88(12 Suppl):2961-2978.
23. Kubota Y., Umegaki K., Kagota S., Tanaka N., Nakamura K., Kunitomo M., et al. Evaluation of blood pressure measured by Tail-Cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull 2006, 29:1756-1758.
24. Williams J.R., Harrison T.R., Grollman A. A simple method for determining the systolic blood pressure of the un-anaesthetized rat. J Clin Invest 1939, 18:373-376.
25. Roullet J.B., Xue H., Chapman J., McDougal P., Roullet C.M., McCarron D.A. Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J Clin Invest 1996, 97:2384-2390.
26. Nagao T., Illiano S., Vanhoutte P.M. Heterogeneous distribution of endothelium-dependent relaxations resistant to NG-nitro-l-arginine in rats. Am J Physiol 1992, 263:H1090-H1094.
27. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999, 96:133-138.
28. Virtanen S.S., Väänänen H.K., Härkönen P.L., Lakkakorpi P.T. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002, 62:2708-2714.
29. Mount P.F., Kemp B.E., Power D.A. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 2007, 42:271-279.
30. Shiga N., Hirano K., Hirano M., Hishimura J., Nawata H., Kanaide H. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ Res 2005, 96:1014-1021.
31. Moriki N., Ito M., Seko T., Kureishi Y., Okamoto R., Nakakuki T., et al. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens Res 2004, 27:263-270.
32. Seko T., Ito M., Kureishi Y., Okamato R., Moriki N., Onishi K., et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 2003, 92:411-418.
33. Laufs U., Endres M., Stagliano N., Amin-Hanjani S., Chui D.S., Yang S.X., et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 2000, 106:15-24.
34. Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A. Non-lipid-related effects of statins. Ann Med 2000, 32:164-176.
35. Laufs U., Liao J.K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000, 10:143-148.
36. Lefer A.M., Scalia R., Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001, 49:281-287.
37. Liao J.K. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002, 86:5-18.
38. Yang D., Feletou M., Levens N., Zhang J.N., Vanhoutte P.M. A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension 2003, 41:143-148.